Patents by Inventor Lone Ottesen

Lone Ottesen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EZH2 INHIBITORS FOR TREATING LYMPHOMA
    Publication number: 20240058348
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Application
    Filed: March 23, 2023
    Publication date: February 22, 2024
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Danielle Johnston BLACKWELL, Larisa REYDERMAN, Lone OTTESEN
  • EZH2 inhibitors for treating lymphoma
    Patent number: 11642347
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: May 9, 2023
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Heike Keilhack, Sarah K. Knutson, Danielle Johnston Blackwell, Larisa Reyderman, Lone Ottesen
  • EZH2 INHIBITORS FOR TREATING LYMPHOMA
    Publication number: 20200323866
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Application
    Filed: March 4, 2020
    Publication date: October 15, 2020
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Danielle Johnston BLACKWELL, Larisa REYDERMAN, Lone OTTESEN
  • EZH2 INHIBITORS FOR TREATING LYMPHOMA
    Publication number: 20200022987
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Application
    Filed: June 27, 2019
    Publication date: January 23, 2020
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Danielle Johnston BLACKWELL, Larisa REYDERMAN, Lone OTTESEN
  • EZH2 INHIBITORS FOR TREATING LYMPHOMA
    Publication number: 20190175604
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Application
    Filed: November 6, 2018
    Publication date: June 13, 2019
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Danielle Johnston BLACKWELL, Larisa REYDERMAN, Lone OTTESEN
  • EZH2 inhibitors for treating lymphoma
    Patent number: 10166238
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: January 1, 2019
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Heike Keilhack, Sarah K. Knutson, Danielle Johnston Blackwell, Larisa Reyderman, Lone Ottesen
  • METHODS OF TREATING CANCER
    Publication number: 20180280470
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.
    Type: Application
    Filed: January 3, 2018
    Publication date: October 4, 2018
    Applicants: Five Prime Therapeutics, Inc., GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Julie Hambleton, Maureen Bleam, Maurice P. DeYoung, Geraldine Ferron-Brady, Rakesh Kumar, Lone Ottesen
  • EZH2 INHIBITORS FOR TREATING LYMPHOMA
    Publication number: 20170216300
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Application
    Filed: June 17, 2015
    Publication date: August 3, 2017
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, L. Danielle JOHNSTON, Larisa REYDERMAN, Lone OTTESEN
  • METHODS OF TREATING CANCER
    Publication number: 20160067307
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.
    Type: Application
    Filed: April 30, 2014
    Publication date: March 10, 2016
    Inventors: Julie Hambleton, Maureen R. Bleam, Maurice P. DeYoung, Geraldine Ferron-Brady, Rakesh Kumar, Lone Ottesen
  • METHODS OF TREATING CANCER
    Publication number: 20130252956
    Abstract: Methods for treating a human having heptocellular carcinoma comprising administering to the human a therapeutically effective amount of Compound A: or a pharmaceutically acceptable salt thereof, wherein the human has a complete response or partial response.
    Type: Application
    Filed: November 21, 2011
    Publication date: September 26, 2013
    Inventors: Howard Kallender, Lone Ottesen